Table 3.
Implementation factors |
Data gaps (based on publicly available, accessible data sources) |
Possible data sources with illustrative examples22 30 |
Availability of NGS tests for clinical use |
|
Published journal articles For example, Article from global collaborative that focuses on enabling the implementation of genomic medicine Grey literature* For example., Online news source such as GenomeWeb that reports on genomic test availability and utilisation Administrative and clinical data† For example, Registries such as the US National Institutes of Health (NIH) Genetic Testing Registry that consists of voluntary submissions by laboratories of their available tests |
Utilisation (# tests ordered) |
|
Published journal articles For example, Article that describes US genetic test availability and spending based on claims data Grey literature* For example, Market reports such as investor analyses of NGS Market by product type Administrative and clinical data† For example, white papers such as Personalised Medicine Coalition’s report that used data integrated from claims, census and proprietary databases |
Funding |
|
Published journal articles For example, Article that reviewed coverage policies for ctDNA (liquid biopsy) tests Grey literature* For example, Advocacy group website such as Coalition for Access to Prenatal Screening Administrative and clinical data† For example, Proprietary and academic databases such as those developed by TRANSPERS and Canary Insights |
*Includes white papers, health system reports, market analyses, regulatory filings, company websites, news reports, national/international consortia websites.
†Includes electronic health records, claims data, fee schedules, industry databases, registries.
NGS, next-generation genomic sequencing.